ReviewCurrent atherosclerosis reports2022
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease.
Review in Current atherosclerosis reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Risk Factors and Prediction Models for Nonalcoholic Fatty Liver Disease Based on Random Forest.Computational and mathematical methods in medicine · 2022Trial
- White blood cell count to platelet ratio (WBC/PLT) is associated with adverse lipid parameters and lower antioxidants intake in patients with NAFLD.Scientific reports · 2026Article
- Association of Genetic Variants inInternational journal of molecular sciences · 2026Article
- A Global Perspective on Metabolic Dysfunction-Associated Steatotic Liver Disease: From Molecular Mechanisms to Therapeutic Strategy Innovation.Nutrients · 2026Review
- Probiotic intervention attenuates hypercholesterolemia and modulates gut microbiota in high-fat diet-fed rats.World journal of microbiology & biotechnology · 2026Article
- Association of geriatric nutritional risk index with metabolic dysfunction-associated steatotic liver disease and subtypes in Chinese elderly: identification of an overnutrition risk threshold and implications for extended risk stratification.Frontiers in nutrition · 2026Article
- Role of activity and fibrosis in the MASLD atherogenic momentum through advanced lipidomics.PloS one · 2026Article
- From Bench to Bedside: Multifunctional Nanoplatforms in the Fight Against Non-alcoholic Fatty Liver Disease.International journal of nanomedicine · 2026Review
- Impact of statins on liver transaminases in patients with metabolic dysfunction-associated steatotic liver disease: A 12-month retrospective review.Hepatology forum · 2026Article
- Gut Microbiota and Metabolomics Insights into the Gualou-Xiebai Herb Pair for Dyslipidemia and Atherosclerosis.Journal of microbiology and biotechnology · 2025Article
- Association between atherosclerosis-related indicators and fatty liver: a population-based observational study.European journal of medical research · 2025Observational
- Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends.World journal of gastrointestinal pharmacology and therapeutics · 2025Review
- Fenofibrate differentially activates PPARα-mediated lipid metabolism in rat kidney and liver.Scientific reports · 2025Article
- Screening for metabolic-associated fatty liver disease in type 2 diabetes patients using non-invasive scores and ultrasound: a cross-sectional study in Egypt.BMC gastroenterology · 2025Article
- Fetuin-A as a Link Between Dyslipidemia and Cardiovascular Risk in Type 2 Diabetes: A Metabolic Insight for Clinical Practice.Biomedicines · 2025Article
- Structure Modeling and Virtual Screening with HCAR3 to Discover Potential Therapeutic Molecules.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Platelet-derived growth factor receptor-β as a non-invasive biomarker for liver fibrosis prediction in Egyptian diabetic patients with metabolic-associated fatty liver disease.BMC gastroenterology · 2025Article
- Therapeutic Potential of Infrared and Related Light Therapies in Metabolic Diseases.International journal of molecular sciences · 2025Review
- Flexible Parametric Survival Modeling of Transaminases as Predictive Biomarkers for Non-Alcoholic Fatty Liver Disease: A Retrospective Longitudinal Study (2012-2022).International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPatients with non-alcoholic fatty liver disease (NAFLD), often considered as the hepatic manifestation of the metabolic syndrome, represent a population at high cardiovascular risk and frequently suffer from atherogenic dyslipidemia. This article reviews the pathogenic interrelationship between NAFLD and dyslipidemia, elucidates underlying pathophysiological mechanisms and focuses on management approaches for dyslipidemic patients with NAFLD. RECENT
findingsAtherogenic dyslipidemia in patients with NAFLD results from hepatic and peripheral insulin resistance along with associated alterations of hepatic glucose and lipoprotein metabolism, gut dysbiosis, and genetic factors. Since atherogenic dyslipidemia and NAFLD share a bi-directional relationship and are both major driving forces of atherosclerotic cardiovascular disease (ASCVD) development, early detection and adequate treatment are warranted. Thus, integrative screening and management programs are urgently needed. A stepwise approach for dyslipidemic patients with NAFLD includes (i) characterization of dyslipidemia phenotype, (ii) individual risk stratification, (iii) definition of treatment targets, (iv) lifestyle modification, and (v) pharmacotherapy if indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.